Tamoxifen therapy in advanced/recurrent endometrial carcinoma.
Forty-nine patients with advanced/recurrent endometrial carcinoma were treated with Tamoxifen, 20 mg, twice daily. There were six complete and four partial responses (response rate = 20%). The median survival of responders was 34 months compared to 6 months in nonresponders. Toxicity was minimal.
Quinn
M A
MA
Gynaecology Unit, Peter MacCallum Cancer Institute, Melbourne, Australia.
Campbell
J J
JJ
D000230:Adenocarcinoma / Q000188:drug therapy* / Q000401:mortality; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002291:Carcinoma, Papillary / Q000188:drug therapy / Q000401:mortality; D002294:Carcinoma, Squamous Cell / Q000188:drug therapy / Q000401:mortality; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000188:drug therapy* / Q000401:mortality; D013629:Tamoxifen / Q000627:therapeutic use*; D014594:Uterine Neoplasms / Q000188:drug therapy* / Q000401:mortality
D013629:Tamoxifen